Matsumoto Yoshihiko, Fabbri Chiara, Pellegrini Silvia, Porcelli Stefano, Politi Pierluigi, Bellino Silvio, Iofrida Caterina, Mariotti Veronica, Melissari Erika, Menchetti Marco, Martinelli Valentina, Cappucciati Marco, Bozzatello Paola, Brignolo Elena, Brambilla Paolo, Balestrieri Matteo, Serretti Alessandro
Department of Biomedical and Neuromotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123, Bologna, Italy.
Mol Diagn Ther. 2014 Oct;18(5):567-77. doi: 10.1007/s40291-014-0110-7.
Several gene variants have been related to major depressive disorder (MDD) treatment outcomes; however, few studies have investigated a possible different effect on pharmacotherapy and brief psychotherapy response.
A total of 137 MDD patients were randomized to either interpersonal counseling (IPC; n = 40) or antidepressant pharmacological treatment (n = 97). Outcomes were remission, response, and symptom improvement at week 8. Five genetic variants were investigated (5HTR2A rs6314, BDNF rs6265, SLC6A4 rs8076005, CREB1 rs2253206, and TPH2 rs11179023) as possible modulators of outcomes.
The LC6A4 rs8076005 AA genotype and A allele were associated with response rate in the antidepressant group (p = 0.015 and 0.005, respectively) and in the whole sample (p = 0.03 and 0.02, respectively). In the IPC group a non-significant trend in the same direction was observed. The TPH2 rs11179023 A allele showed a marginal association with symptom improvement in the IPC group only. Other gene variants did not impact on outcomes in any treatment group.
Our study suggests that rs8076005 in the SLC6A4 gene may be a modulator of antidepressant response, especially when pharmacological treatment is used.
多种基因变异与重度抑郁症（MDD）的治疗结果相关；然而，很少有研究调查其对药物治疗和简短心理治疗反应可能存在的不同影响。
总共137名MDD患者被随机分为人际咨询组（IPC；n = 40）或抗抑郁药物治疗组（n = 97）。观察第8周时的缓解情况、反应情况和症状改善情况。研究了5种基因变异（5HTR2A rs6314、BDNF rs6265、SLC6A4 rs8076005、CREB1 rs2253206和TPH2 rs11179023）作为可能的结果调节因子。
SLC6A4 rs8076005的AA基因型和A等位基因与抗抑郁药物治疗组的反应率相关（分别为p = 0.015和0.005），在整个样本中也相关（分别为p = 0.03和0.02）。在IPC组中观察到相同方向的非显著趋势。TPH2 rs11179023的A等位基因仅与IPC组的症状改善有边缘关联。其他基因变异对任何治疗组的结果均无影响。
我们的研究表明，SLC6A4基因中的rs8076005可能是抗抑郁反应的调节因子，尤其是在使用药物治疗时。
